Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 1/20 | 0.65 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.65 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.65 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.65 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.65 |
| ▸ | PKM | P14618 | 3/20 | 0.61 |
| ▸ | FOLH1 | Q04609 | 5/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.56 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | ABL1 | P00519 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | IDE | P14735 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18025039 | 0.96 | F2 (0.67) | F2PRSS1PRSS2PRSS3TPSAB1 | |
| SCHEMBL10110855 | 0.96 | F2 (0.67) | F2PRSS1PRSS2PRSS3TPSAB1 | |
| SCHEMBL15216220 | 0.90 | F2 (0.73) | F2PRSS1PRSS2PRSS3TPSAB1 | |
| SCHEMBL19017236 | 0.90 | F2 (0.73) | F2PRSS1PRSS2PRSS3TPSAB1 | |
| SCHEMBL4968230 | 0.90 | F2 (0.73) | F2PRSS1PRSS2PRSS3TPSAB1 | |
| SCHEMBL19751698 | 0.90 | F2 (0.73) | F2PRSS1PRSS2PRSS3TPSAB1 | |
| SCHEMBL10126107 | 0.90 | F2 (0.69) | F2PRSS1PRSS2PRSS3TPSAB1 | |
| SCHEMBL16602282 | 0.90 | F2 (0.71) | F2PRSS1PRSS2PRSS3TPSAB1 | |
| SCHEMBL18612883 | 0.89 | F2 (0.67) | F2PRSS1PRSS2PRSS3TPSAB1 | |
| SCHEMBL16075601 | 0.89 | F2 (0.67) | F2PRSS1PRSS2PRSS3TPSAB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9333232-B2 | Methods for treating papilloma virus infection | NANOVIR LLC (US) | 2016-05-10 | — | — | US | disclosed |
| US-9290551-B2 | Compounds for treating papilloma virus infection | NANOVIR LLC (US) | 2016-03-22 | — | — | US | disclosed |
| US-20150239943-A1 | COMPOUNDS FOR TREATING PAPILLOMA VIRUS INFECTION | THE CURATORS OF THE UNIVERSITY OF MISSOURI | 2015-08-27 | — | — | US | disclosed |
| US-8993609-B2 | Compounds for treating papilloma virus infection | NANOVIR, LLC (US) | 2015-03-31 | — | — | US | disclosed |
| US-20120225809-A1 | COMPOUNDS FOR TREATING PAPILLOMA VIRUS INFECTION | NANOVIR, LLC (US) | 2012-09-06 | — | — | US | disclosed |
| US-8119677-B2 | Polyamides containing amino butyric acid-based building blocks | NANOVIR, LLC (US) | 2012-02-21 | — | — | US | disclosed |
| US-20100015084-A1 | Compounds for Treating Papilloma Virus Infection | NANOVIR, LLC (US) | 2010-01-21 | — | — | US | disclosed |
| US-20090306164-A1 | Methods for Treating Papilloma Virus Infection | NANOVIR, LLC (US) | 2009-12-10 | — | — | US | disclosed |
| US-7589171-B2 | Polyamides for treating human papilloma virus | NANOVIR, LLC (US) | 2009-09-15 | — | — | US | disclosed |
| US-20070293417-A1 | Polyamides for treating human papilloma virus | NANOVIR, LLC | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225809-A1 | COMPOUNDS FOR TREATING PAPILLOMA VIRUS INFECTION | POLI, TLR3, PMAIP1 | F2 4719/4885PRSS1 317/4885PRSS2 652/4885 |
| US-20090306164-A1 | Methods for Treating Papilloma Virus Infection | POLI, VHL, TLR3 | F2 4324/4885PRSS1 538/4885PRSS2 709/4885 |
| US-20150239943-A1 | COMPOUNDS FOR TREATING PAPILLOMA VIRUS INFECTION | POLI, TLR3, PMAIP1 | F2 4719/4885PRSS1 317/4885PRSS2 652/4885 |
| US-20100015084-A1 | Compounds for Treating Papilloma Virus Infection | POLI, PMAIP1, TLR3 | F2 4798/4885PRSS1 384/4885PRSS2 909/4885 |
| US-20070293417-A1 | Polyamides for treating human papilloma virus | POLI, PARG, PARN | F2 4845/4885PRSS1 783/4885PRSS2 1395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.